Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He then completed his Medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in Medical oncology.
Professor Hussain is Professor and Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up a large number of clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001), to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. Professor Hussain is principal investigator of number of studies in urological cancers. He is a chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer. He served as chief investigator of various early phase trials, and translational studies. Professor Hussain has authored over 100 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 33 with over 8300 citations. He has published in high impact journals including New England Journal of medicine, Lancet, Lancet Oncology, JAMA Oncology, Journal of Clinical oncology, European Urology, Annals of Oncology, Clinical Cancer Research, British journal of Cancer. He has been an invited speaker to number of national and international meetings. Professor Hussain has secured funding of over 10 million pounds from funding bodies.